(Q34431964)

2 August 2017

title

Epigenetic drugs against cancer: an evolving landscape (English)

1 reference

2 August 2017

Antimo Migliaccio

3

0 references

Lucia Altucci

object named as

Lucia Altucci

series ordinal

4

0 references

author name string

Antonella Di Costanzo

series ordinal

1

1 reference

2 August 2017

Nunzio Del Gaudio

series ordinal

2

1 reference

2 August 2017

publication date

2 August 2014

1 reference

2 August 2017

published in

Archives of Toxicology

1 reference

2 August 2017

volume

88

1 reference

2 August 2017

issue

9

1 reference

2 August 2017

page(s)

1651-1668

1 reference

New nomenclature for chromatin-modifying enzymes

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

MG98, a second-generation DNMT1 inhibitor, in the treatment of advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Phase I trial of a new schedule of romidepsin in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Resveratrol-sulfates provide an intracellular reservoir for generation of parent resveratrol, which induces autophagy in cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Small molecule modulators of histone acetyltransferase p300.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Regulation of chromatin by histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Highly ligand efficient and selective N-2-(Thioethyl)picolinamide histone deacetylase inhibitors inspired by the natural product psammaplin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

An essential role for DNA methyltransferase DNMT3B in cancer cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Identification of a small molecule inhibitor of Sir2p

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Curcumin, resveratrol and flavonoids as anti-inflammatory, cyto- and DNA-protective dietary compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

The promise and failures of epigenetic therapies for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Rejuvenating sirtuins: the rise of a new family of cancer drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Sirtuins inhibitors: the approach to affinity and selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Dnmt3a is essential for hematopoietic stem cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Inhibition of DNA methylation and reactivation of silenced genes by zebularine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

The histone deacetylase inhibitor MGCD0103 has both deacetylase and microtubule inhibitory activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Targeting epigenetic readers in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Vorinostat in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Cancer epigenomics: DNA methylomes and histone-modification maps

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

21 January 2018

Epigenetics in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Selective inhibition of BET bromodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Recent progress in the biology and physiology of sirtuins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Histone demethylation catalysed by LSD1 is a flavin-dependent oxidative process

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

The class I-specific HDAC inhibitor MS-275 modulates the differentiation potential of mouse embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

DNA methyltransferase inhibitors-state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Anti-tumoral effect of the non-nucleoside DNMT inhibitor RG108 in human prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Chemosensitization of tumors by resveratrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Discovery of curcumin, a component of golden spice, and its miraculous biological activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Epigenetic aberrations during oncogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Chromatin proteins and modifications as drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Identification of Selective Inhibitors of NAD+-dependent Deacetylases Using Phenotypic Screens in Yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Histone lysine demethylases as targets for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Solution structure of the second bromodomain of Brd2 and its specific interaction with acetylated histone tails

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

De novo CpG island methylation in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

The epigenomics of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

SIRT1 controls circadian clock circuitry and promotes cell survival: a connection with age-related neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Failure of hypomethylating agent-based therapy in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

A decade of histone acetylation: marking eukaryotic chromosomes with specific codes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Chromatin modifications and their function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Procainamide is a specific inhibitor of DNA methyltransferase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

DNMT3A Mutations in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Discovery of a 2,4-Diamino-7-aminoalkoxyquinazoline as a Potent and Selective Inhibitor of Histone Lysine Methyltransferase G9a

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

The therapeutic uses of chromatin-modifying agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Activation of p300 histone acetyltransferase by small molecules altering enzyme structure: probed by surface-enhanced Raman spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Decitabine for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Histone deacetylase inhibitors as new cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Structural studies on human 2-oxoglutarate dependent oxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Suramin: clinical uses and structure-activity relationships.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2'-deoxycytidine on ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Targeting MYC dependence in cancer by inhibiting BET bromodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

DNA methylation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

21 January 2018

Epigenetics and oncology

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Generation of hydrogen peroxide primarily contributes to the induction of Fe(II)-dependent apoptosis in Jurkat cells by (-)-epigallocatechin gallate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

DNA methyltransferase inhibitor zebularine inhibits human hepatic carcinoma cells proliferation and induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Trials with 'epigenetic' drugs: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Garcinol, a histone acetyltransferase inhibitor, radiosensitizes cancer cells by inhibiting non-homologous end joining

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Sensitization of tumor cells by targeting histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

5-hydroxymethylcytosine and its potential roles in development and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Psammaplins from the Sponge Pseudoceratina purpurea: Inhibition of Both Histone Deacetylase and DNA Methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

A new path to the cancer epigenome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

DNA methylation, methyltransferases, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Cancer epigenetics reaches mainstream oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Multivalent engagement of chromatin modifications by linked binding modules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Bisubstrate analogue structure-activity relationships for p300 histone acetyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Inhibition of lysine-specific demethylase 1 by the acyclic diterpenoid geranylgeranoic acid and its derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

DNA methyltransferase inhibitor RG108 and histone deacetylase inhibitors cooperate to enhance NB4 cell differentiation and E-cadherin re-expression by chromatin remodelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Solving the Dnmt2 enigma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

RNA methylation by Dnmt2 protects transfer RNAs against stress-induced cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Resveratrol and cellular mechanisms of cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Histone deacetylase inhibitors: structure-based modeling and isoform-selectivity prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Reduced expression of oestrogen receptor β in invasive breast cancer and its re‐expression using DNA methyl transferase inhibitors in a cell line model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Chemical mechanisms of histone lysine and arginine modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

shRNA screening identifies JMJD1C as being required for leukemia maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Discovery and Development of Potent and Selective Inhibitors of Histone Methyltransferase G9a

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

The journey of resveratrol from yeast to human

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Identification of cell-active lysine specific demethylase 1-selective inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Sirtuin activators and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

DNA demethylating agents and chromatin-remodelling drugs: which, how and why?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Resveratrol in cardiovascular disease: what is known from current research?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Cytostatic and apoptotic effects of DNMT and HDAC inhibitors in endometrial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Resveratrol inhibits the growth of gastric cancer by inducing G1 phase arrest and senescence in a Sirt1-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Molecular Pathways: The Complexity of the Epigenome in Cancer and Recent Clinical Advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

Design, Synthesis, and Biological Evaluation of 2-Aminobenzanilide Derivatives as Potent and Selective HDAC Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1315-6

10.1007/S00204-014-1315-6

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1035721021

0 references

1 reference